Dovato

Dovato is available as tablets containing 50 mg of dolutegravir and 300 mg of lamivudine. The patient should take one tablet once a day. For more information about using Dovato, see the package leaflet or contact your doctor or pharmacist.

Dovato can only be obtained with a prescription and should be prescribed by a doctor who is experienced in managing HIV infection.

The two active substances in Dovato, dolutegravir and lamivudine, block the activity of enzymes that the virus uses to make new copies of itself. Dolutegravir stops the activity of an enzyme called integrase (and is known as an integrase inhibitor), while lamivudine stops the activity of reverse transcriptase (and is known as a nucleoside reverse transcriptase inhibitor or NRTI).

Both active substances have already been authorised in the European Union as separate tablets: dolutegravir in 2014 and lamivudine in 1996.

Dovato does not cure HIV infection or AIDS, but it may hold off damage to the immune system and the development of infections and diseases associated with AIDS.

Two main studies, involving 1,441 patients, have shown that the combination of the two active substances in Dovato is as effective at lowering the amount of HIV in the blood as a triple combination therapy (dolutegravir plus tenofovir plus emtricitabine).

In these studies, 91% of patients with HIV-1 who took the Dovato combination no longer had detectable levels of HIV (below 50 copies per ml) after 48 week compared with 93% of those who were taking the triple combination. In both studies there were no cases of resistance to treatment after 48 weeks.

The most common side effects with Dovato (which may affect up to 1 in 10 people) are headache, diarrhoea, nausea and difficulty sleeping. The most common serious side effects (which may affect up to 1 in 100 people) are allergic reactions, including rash and severe liver problems.

For the full list of side effects and restrictions, see the package leaflet.

Triple combination therapy is used for HIV treatment to reduce the chance of the virus becoming resistant to treatment. In two main studies, the Dovato combination was just as effective as a triple combination in patients with HIV-1, with no cases of resistance developing in these patients. Furthermore, both active substances are available in a single tablet and are acceptably safe.The European Medicines Agency therefore decided that Dovato’s benefits are greater than its risks and that it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dovato have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Dovato are continuously monitored. Side effects reported with Dovato are carefully evaluated and any necessary action taken to protect patients.

Dovato received a marketing authorisation valid throughout the EU on 1 July 2019.